CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED TEXT OMITTED FROM THIS EXHIBIT IS MARKED WITH [***] License and Supply Agreement...License and Supply Agreement • June 30th, 2021 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS LICENSE and SUPPLY AGREEMENT (this “Agreement”) is made as of June 28, 2021 (the “Effective Date”) by and between Catalyst Pharmaceuticals, Inc., 355 Alhambra Circle, Suite 801 Coral Gables, Florida, a corporation incorporated under the laws of the state of Delaware, United States of America (“CATALYST”), and DyDo Pharma, Inc., 2-2-7 Nakanoshima, Kita-ku, Osaka, a corporation incorporated under the laws of Japan (“DYDO”).
